Researchers who used F-18 FDG-PET/CT found that people with newly diagnosed follicular lymphoma undergoing rituximab-based chemoimmunotherapy who had positive scans had 39.9 months of median progression-free survival at an interim evaluation point and 14.2 months of median PFS at end-of-induction therapy, compared with 55.5 months of median PFS at interim and 60.5 months of median PFS at EOI among those with negative scans. Multivariate analysis of the findings, which were published in the journal Nuclear Medicine and Molecular Imaging, showed that PET status at EOI alone independently predicted follicular lymphoma progression.
F-18 FDG-PET/CT examined in predicting follicular lymphoma progression
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.